(Rac) -ZLc-002

(Rac) -ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability[1][2].

Product Specifications

UNSPSC

12352211

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rac-zlc-002.html

Purity

98.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OC)CC(NC(C(OC)=O)C(C)C)=O

Molecular Formula

C10H17NO5

Molecular Weight

231.25

References & Citations

[1]Lee WH, Carey LM, Li LL, et al. ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Mol Pain. 2018;14:1744806918801224.|[2]Zhu LJ, Shi HJ, Chang L, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020;177 (16) :3674-3690.